Head to Head Analysis: Profound Medical (PROF) and Its Peers

Profound Medical (NASDAQ:PROF) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare Profound Medical to similar companies based on the strength of its valuation, profitability, institutional ownership, dividends, analyst recommendations, earnings and risk.

Valuation & Earnings

This table compares Profound Medical and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Profound Medical	$16.10 million	-$42.57 million	-6.70
Profound Medical Competitors	$1.87 billion	$138.21 million	10.70

Profound Medical’s peers have higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Profound Medical has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Profound Medical’s peers have a beta of 2.55, suggesting that their average stock price is 155% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Profound Medical and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1	0	1	1	2.67
Profound Medical Competitors	4251	10479	18202	824	2.46

Profound Medical presently has a consensus target price of $11.50, suggesting a potential upside of 75.04%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.57%. Given Profound Medical’s stronger consensus rating and higher probable upside, research analysts clearly believe Profound Medical is more favorable than its peers.

Insider and Institutional Ownership

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Profound Medical and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profound Medical	-171.57%	-63.03%	-51.24%
Profound Medical Competitors	-278.23%	-150.07%	-21.87%

Summary

Profound Medical peers beat Profound Medical on 7 of the 13 factors compared.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.